目的:探讨CT23及其抗体在女性恶性肿瘤(乳腺癌、卵巢癌、子宫内膜癌)辅助诊断中的应用价值。方法:选取卵巢癌患者65例、乳腺癌患者54例、子宫内膜癌患者35例、盆腔良性肿瘤患者21例及健康对照组70例,通过ELISA检测血清中CT23含量及CT23抗体表达水平。结果:肿瘤组患者的CT23和CT23抗体平均含量均高于健康对照组,其中卵巢癌患者组与健康对照组差异具有统计学意义(P Purpose: To explore the application value of CT23 and its antibody in the auxiliary diagnosis of female malignant tumors (breast, ovarian, endometrial). Methods: A total of 65 patients with ovarian cancer, 54 patients with breast cancer, 35 patients with endometrial cancer, 21 patients with benign pelvic tumors, and 70 healthy controls were selected. The levels of CT23 and CT23 antibody in serum were detected using ELISA. Results: The average levels of CT23 and CT23 antibody in the tumor group were higher than those in the healthy control group, with statistically significant differences in the ovarian cancer patient group (P < 0.001). ROC curve analysis showed that CT23 had limited diagnostic value for female tumors, while CT23 antibody might be a moderate serum marker for breast cancer or ovarian cancer. Conclusion: CT23 antibody has certain reference value in the diagnosis of breast cancer and ovarian cancer, but its clinical significance requires further research and verification.
暂无评论